fingolimod hydrochloride has been researched along with methotrexate in 4 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cozzi, E; Schuurman, HJ; Smith, HT | 1 |
| Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S | 1 |
| Desai, D; Doroszko, M; Eriksson, JE; Kemppainen, K; Niemelä, E; Niemi, R; Özliseli, E; Rahman, NA; Rosenholm, JM; Sahlgren, C; Törnquist, K | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
1 review(s) available for fingolimod hydrochloride and methotrexate
| Article | Year |
|---|---|
Azathioprine in multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; Cyclophosphamide; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Methotrexate; Methyltransferases; Mitoxantrone; Models, Chemical; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2008 |
3 other study(ies) available for fingolimod hydrochloride and methotrexate
| Article | Year |
|---|---|
Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.
Topics: Animals; Cyclophosphamide; Cyclosporine; Drug Synergism; Everolimus; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Macaca fascicularis; Male; Methotrexate; Mycophenolic Acid; Organ Transplantation; Papio; Propylene Glycols; Sirolimus; Sphingosine | 2005 |
Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Delivery Systems; Fingolimod Hydrochloride; Folate Receptors, GPI-Anchored; Humans; Methotrexate; Nanoparticles; Neoplasm Invasiveness; Silicon Dioxide; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |